Inimmune is advancing disruptive disease modifying immunotherapies in the oncology and allergy spaces to improve patient’s lives. We are currently raising a Series B raise to advance our two phase I assets through Phase II. INI-4001, a potent and selective TLR-7/8 agonist, is currently in a phase I trial in cancer patients with solid tumors refractory to check point therapies. INI-4001, in preclinical cancer models, stimulates the innate immune system and synergizes with immune check point therapy to eradicate tumors. This is expected to greatly expand the percentage of patients who will benefit from check point therapy. Our lead allergy therapeutic INI-2004 has completed its multiple ascending dose phase IB trial. Our team is composed of world leaders in innate immune R&D which has resulted in non-dilutive NIH funding (over $140M) over the past 7 years. This NIH funding significantly reduces financial risk and targets investor capital towards advancing our clinical assets.